In the article by Bettinger D, Pinato DJ, Schultheiss M, et al., entitled “Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis” [Liver Cancer, DOI: 10.1159/000490260], the abstract shows some wrong values. The abstract with correct values in bold reads as follows:
Median OS of SBRT patients was 17.0 (9.8–24.2) months compared to 8.8 (8.2–9.5) in sorafenib patients. After adjusting for different baseline characteristics, the survival benefit for patients treated with SBRT was still preserved with a median OS of 16.0 (11.0–21.0) months compared to 9.6 (8.6–10.7) months in sorafenib patients. SBRT treatment of intrahepatic lesions in patients with extrahepatic metastases was also associated with improved OS compared to patients treated with sorafenib in the same setting (16.0 vs. 10.0 months, p = 0.018), whereas in patients with portal vein thrombosis there was no survival benefit in patients with SBRT.